Why is "Cisplatin" trending?

Search Interest Perspective

• DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling | Oncogene - Nature
• Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer - The ASCO Post
• Perioperative Pembrolizumab Plus Enfortumab Vedotin Nets FDA Priority Review in Cisplatin-Eligible MIBC - OncLive
• Cisplatin-based combination therapy for cancer : Journal of Cancer Research and Therapeutics - Ovid
• Cisplatin resistance in oral squamous cell carcinoma: mechanisms, reversal strategies, and emerging technologies - Frontiers
• 'Pro version' of cisplatin keeps its cancer-killing power while reducing side effects - Medical Xpress
• Carboplatin Versus Cisplatin: Analyzing Chemotherapy Strategies in Bladder Cancer Care - Cancer Nursing Today
• Cancer cells surviving cisplatin chemotherapy increase stress-induced OMA1 activity and mitochondrial fragmentation - Nature
• Head and Neck Cancer: Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin - The ASCO Post
• Evaluating the synergistic effects of cisplatin and tamoxifen in canine osteosarcoma cells - Frontiers
• Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin - Nature
• Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - The ASCO Post
• Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer - Nature
• Arvanil reverses cisplatin resistance in ovarian cancer by activating HMOX1-driven ferroptosis - Nature
• PHKG2 confers resistance of ESCC to cisplatin and enhances CXCL8-dependent immunosuppression to exacerbate tumorigenesis - Nature
• SLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescence - Nature
• SOX4 induces cisplatin resistance in cervical cancer cells by inhibiting aerobic glycolysis - Nature
• GATOR1 complex controls cisplatin sensitivity - Nature
• Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells - Nature
• Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer - Nature
• Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC - Targeted Oncology
• Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC - The ASCO Post
• Carboplatin Matches Cisplatin Efficacy With Reduced Toxicity in LA-NPC Chemoradiotherapy - Targeted Oncology
• Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial - Nature
• Eleutheroside E alleviates cisplatin-induced ototoxicity by down-regulating MAPK/NF-κB/NLRP3 signaling pathway and inhibiting cochlear cell pyroptosis - Nature
• pH-triggered liposomal strategy for cisplatin in lung cancer therapy - Nature
• Trial of ACOU085 progresses for cisplatin-induced ototoxicity in testicular cancer - Urology Times
• Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer - News-Medical
• Co-delivery of cisplatin and Bmi1 siRNA via nanocapsules overcomes chemoresistance in ovarian cancer - Nature
• Rechallenge With Cisplatin After an Acute Coronary Event: - JACC Journals
• The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats - Frontiers
• Perioperative Enfortumab Vedotin/Pembrolizumab Meets EFS, OS, pCR End Points in Cisplatin-Eligible MIBC - OncLive
• Enfortumab Vedotin Combo Improves Survival in Cisplatin-Eligible MIBC - CancerNetwork
• Mitochondrial dynamics in cisplatin resistance: molecular mechanisms and therapeutic targeting - Frontiers
• SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer - Nature
• Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models - Nature
• FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC - Wiley & Sons
• Carboplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Cancer - Oncodaily
• SPINK5 promotes sensitivity to cisplatin by inducing ferroptosis in head and neck carcinoma | Cancer Gene Therapy - Nature
• FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care - OncLive
• Short-chain fatty acids mitigate cisplatin-induced sensory damage and hearing loss via MUTYH - Bioengineer.org
• Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - The ASCO Post
• EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab/Enfortumab Vedotin in Cisplatin-Ineligible MIBC - OncLive
• MSU’s federally funded cisplatin cancer drug wins national award - Michigan State University
• Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer - OncLive
• Rational design of cisplatin and carboplatin complexes for enhanced anticancer efficacy based on DFT QTAIM and docking analyses - Nature
• Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC - OncLive
• HCRN GU 20-444: Pembrolizumab After TURBT for Bladder‑Sparing in Cisplatin‑Ineligible MIBC - Jonathan Anker - UroToday
• Graphical Reconstruction Method Compares Neoadjuvant Regimens in Cisplatin-Ineligible MIBC - Brigida Maiorano - UroToday
• TFF3 sensitizes cervical carcinoma cells to cisplatin toxicity by binding to IGF2R - Nature
• Journal of Hepato-Biliary-Pancreatic Sciences | JSHBPS Pancreas Journal - Wiley Online Library
• GDF-15 Blockade May Deepen Neoadjuvant IO Response in Cisplatin-Ineligible MIBC - OncLive
• Pericardial effusion in cancer patients — outcomes of intrapericardial cisplatin instillation: Single-center experience - Via Medica Journals
• KEYNOTE-905 Evaluates Perioperative EV+Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Hristos Kaimakliotis - UroToday
• Why vital chemotherapy drugs are in short supply in India - The Hindu
• Weekly vs Tri-Weekly Cisplatin in Locally Advanced Cervical Cancer: What the TACO Phase III Trial Tells Us - Oncodaily
• Response to cisplatin in a metastatic... : Annals of Oncology Research and Therapy - Ovid
• Kidney function before cisplatin treatment ‘dominant predictor’ for chronic kidney disease - Healio
• Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - The ASCO Post
• MSU’s cisplatin cancer drug wins national award - Michigan State University
• Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost - The ASCO Post
• Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma - The New England Journal of Medicine
• The Role of Tumour Metabolism in Cisplatin Resistance - Frontiers
• Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature - Nature
• TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway - Nature
• ONC201 enhances the cytotoxic effect of cisplatin through ATF3/ATF4/CHOP in head and neck squamous cell carcinoma cells - Nature
• Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial - Nature
• A Novel Approach for Cisplatin-Resistant Esophageal Squamous Cell Carcinoma via Amino Acid Transporter LAT1 Inhibition - Wiley Online Library
• Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity - Science | AAAS
• Apoptosis, autophagy, ferroptosis, and pyroptosis in cisplatin-induced ototoxicity and protective agents - Frontiers
• Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis - Nature
• Price hike for cisplatin, carboplatin, and tetanus injections in India - The News Mill
• To ease cancer drug shortage, FDA will allow imports from China - NBC News
• First-Line Treatment of Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: The Pursuit of Improved Outcomes - ASCO Daily News
• Algorithm Proposed to Expand Cisplatin Eligibility for MIBC - Renal and Urology News
• How a critical cancer drug became hard to find in the U.S. - NBC News
• Potential Cause of Cisplatin-Linked Hearing Loss Identified - National Cancer Institute (.gov)
• Cisplatin nephrotoxicity: new insights and therapeutic implications - Nature
• Cisplatin vestibulotoxicity: a current review - Frontiers
• Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity - Nature
• Cisplatin toxicity is counteracted by the activation of the p38/ATF-7 signaling pathway in post-mitotic C. elegans - Nature
• Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer - NEJM Evidence
• Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer - The New England Journal of Medicine
• Defining Cisplatin Eligibility in Patients with Muscle-Invasive Bladder Cancer - Beyond the Abstract - UroToday
• NIAGARA: Perioperative Durvalumab Plus Neoadjuvant Cisplatin Gemcitabine Chemotherapy Shows OS Benefit in MIBC - ASCO Daily News
• Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study - Nature
• Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma - The New England Journal of Medicine
• Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial - Nature
• Studies on the mechanism of ototoxic action of cisplatin and the antagonistic effect of polyphenolic compounds - Frontiers
• SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway - Nature
• Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss - The New England Journal of Medicine
• Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review - Frontiers
• Cardiovascular Toxicity With Cisplatin in Patients With Testicular Cancer: - JACC Journals
• Notch1 promotes resistance to cisplatin by up-regulating Ecto-5′-nucleotidase (CD73) in triple-negative breast cancer cells - Nature
• Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo - Nature
• Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism - Nature
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
• Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer - The New England Journal of Medicine
• Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1/2 to Cisplatin-based chemotherapy - Nature
• The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma - Frontiers